For years, myopia was framed, and treated, as a refractive condition. Today, it has officially been reframed as a medical condition, and that changes everything.

We all know the traditional story: A child becomes nearsighted, receives glasses, and returns a year later for another prescription update. But that model is rapidly evolving, and as eyecare professionals, we have an opportunity to change the trajectory of these young patients' lives.

It is exciting to see how far we have come since the first FDA-approved myopia management treatment became available in 2019. As our understanding of myopia continues to advance, practices are shifting from simply correcting vision to actively managing a chronic disease. The conversation is no longer centered on how many diopters a child added this year. It has evolved to understanding axial length, millimeters, and reducing lifelong risk of ocular complications.

In other words, myopia management is no longer a diopter game; it is a millimeter game.

This shift represents one of the most significant clinical and business opportunities in eye care today.

From Transactions to Ongoing Care

Historically, myopia care followed a reactive model. A child's prescription changed, and we responded with a stronger prescription.

Myopia management requires a proactive approach.

Practices that successfully implement myopia management create ongoing care relationships that include regular monitoring, treatment adjustments, patient education, and long-term follow-up. Rather than seeing children once a year for a new pair of glasses, providers become partners in protecting a child's future eye health.

This transition benefits patients, parents, and practices alike. Families receive a higher level of care, while practices develop stronger retention, increased patient lifetime value, and deeper trust with parents who appreciate having a guide through an often-confusing journey.

Getting to "Yes" Faster

One of the biggest barriers to adoption is not cost—it is confusion. Every practice should recognize that a parent's "no" is often an “I don’t know” in disguise.

When parents leave the practice feeling uncertain, treatment is delayed while their child's myopia continues to progress.

Successful practices focus on simplifying decisions. Rather than overwhelming families with every possible treatment option, they educate parents about the condition, explain the risks of progression, and confidently recommend the option they believe is best for that child and family.

Parents do not need more information. They need clarity.

The goal is not to present a menu and leave the decision entirely up to them. Parents already have enough decisions to make every day. Our responsibility is to guide the conversation, make a recommendation, and help them start treatment as early as possible.

Preparing for the FAQ

Myopia management conversations become easier when doctors and staff intentionally practice them.

Every team member should be prepared to answer common concerns:

• "Can't we wait to see what happens?" Waiting is often the riskiest option. Myopia progression is generally easier to slow when intervention begins earlier, and once axial elongation occurs, we cannot reverse it.

• "Why have I never heard of this before?" Awareness of myopia management has accelerated dramatically over the past decade as research and treatment options have expanded.

• "Why doesn't insurance cover this?" Many myopia management treatments focus on reducing future disease risk rather than correcting current vision. Insurance reimbursement often lags behind advances in clinical care.

• "Can we pay over time?" Payment plans and financing options can remove a major barrier to care. Families routinely finance braces and orthodontics for their children. Myopia management deserves similar consideration.

• "Why is it important to do something now?" Every year of unmanaged progression increases the likelihood of higher myopia and greater lifetime risk of retinal detachment, myopic maculopathy, glaucoma, and other ocular complications.

• "Can I get a second opinion?" Absolutely. Parents should feel comfortable seeking additional information. In many cases, a second opinion reinforces the recommendation and increases confidence in moving forward.

Building a Team-Based Program

From the moment a parent calls the office through enrollment and ongoing treatment, myopia management is a team sport. The most successful practices recognize that the doctor cannot carry the entire program alone. Education should occur throughout the patient journey, not just during the doctor's exam: Technicians can introduce the concept. Opticians can reinforce recommendations. Patient coordinators can discuss financing and scheduling. Administrative staff can support follow-up and reactivation efforts.

Not every parent will say “yes” immediately. If a family declines treatment, the conversation should not end. Schedule the next visit, share educational resources, and continue demonstrating genuine concern for the child's long-term eye health.

Remember, persistence is not pressure. It is patient advocacy.

The Future of Pediatric Eye Care

Myopia management is transforming both clinical care and practice economics. It creates recurring care relationships, strengthens patient loyalty, and positions practices as leaders in preventive eye health.

Most importantly, it changes outcomes for children.

I often ask audiences a simple question: If a 7-year-old presents today as a -1.50 D myope, who would bet $100 that child will still be a -1.50 D at age 18? No one takes that bet.

Because we know better.

A -11.00 D 12-year-old sitting in our chair today was not a -11.00 D 6 years ago. While she needed stronger glasses back then, what she really needed was a doctor willing to start treatment when she was a -3.00 D.

When we stop focusing solely on diopters and start focusing on millimeters, we change the conversation. More importantly, we change a child's future—and that is a pretty remarkable place for our profession to be.

Brianna Rhue, OD, FAAO, FSLS, completed her residency at the Bascom Palmer Eye Institute in Miami and is the owner of West Broward Eyecare in South Florida. Dr. Rhue is the co-founder of Dr. Contact Lens, which made the INC 5000 list in 2023 and 2024.